Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PhageBank Therapy for Chronic Prosthetic Joint Infection
NCT05269121Phase 2Withdrawn
- Sponsor
- BiomX
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Single Strain Products, Multi-strain Products
01
Overview
Phase 2, open-label, single-arm trial of PhageBank in prosthetic joint infection (PJI), sponsored by BiomX. Primary endpoints: Safety and tolerability of phage therapy and Treatment success at 13 months. Planned start Sep 2022; status: withdrawn.
02
Drugs
PhageBank
03
Conditions
prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT05269121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269121.